Clinical Trials · NCT02941367
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 184
- Start date
- Feb 2017
- Locations
- 16 sites, 4 countries
- Primary endpoint
- Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L)